Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium
- 8 Downloads
The aim of this study was to investigate the effect of daptomycin against vancomycin-resistant Enterococcus faecium bacteraemia using computer modelling.
Data obtained in vitro from time-kill curves were evaluated by PK/PD modelling and Monte Carlo simulations to determine the logarithmic reduction in the number of colony-forming units (CFU)/mL over 18 days of daptomycin treatment at 6, 8, and 10 mg/kg doses every 24 or 48 h and with variations in creatinine clearance (CLCR) of 15–29, 30–49, and 50–100 mL/min/1.73 m2. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA) for an area under the unbound drug concentration-time curve/minimum inhibitory concentration (fAUC/MIC) > 36 at the same doses and CLCR.
Static time-kill model was employed to investigate the antibacterial efficacy of constant daptomycin concentrations. The time-kill curve analysis was performed using mathematical modelling based on a Hill coefficient factor. There was an expressive reduction (> 2 Log CFU/mL) over 18 days of daptomycin treatment in 75th percentile of individuals with CLCR of 15–100 mL/min/1.73 m2) with daptomycin 6–10 mg/kg/day, except for daptomycin every 48 h. Using fAUC/MIC > 36, PTA was > 90% at MICs ≤ 2 μg/mL.
Higher daptomycin doses were associated with higher mortality in time-kill curves. The simulations indicated that independent of the CLCR the therapeutic responses of VRE occur with doses of daptomycin ≥ 6 mg/kg/day and daptomycin every 48 h is insufficient to treat enterococcal bacteraemia.
KeywordsDaptomycin Bacteraemia Enterococcus faecium PK/PD modelling
All authors were involved in the content development of the manuscript, reviewed all drafts, and approved the final version.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 6.Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A et al (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34:1–14CrossRefGoogle Scholar
- 13.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty fourth informational supplement (2017) CLSI document M100-S27. Wayne, PennsylvaniaGoogle Scholar
- 18.Pachaly JR, Fernando H, De Brito V (2001) Interspecific allometric scaling. In: Murray E, Fowler DVM (eds) Biology, medicine and surgery of South American wild animals. Iowa State University Press, Ames, Iowa, pp 475–481Google Scholar
- 20.EUCAST. 2017. Available at: http://www.eucast.org/clinical_breakpoints/ (last accessed 15 May 2019).
- 25.Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP (2018) Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model. Antimicrob Agents Chemother 24:e00506–e00518Google Scholar
- 26.Chong PP, Duin DV, Bangdiwala A, Ivanova A, Miller WC, Weber DJ et al (2016) Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg/L. Clin Ther 38:2468–2476CrossRefGoogle Scholar
- 33.Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, Evans R (2012) Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 56(11):5626–5632CrossRefGoogle Scholar